TORONTO, May 17, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a feasibility agreement with LTS Lohmann Therapie-Systeme AG (“LTS”)…


Previous articleMindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial
Next articleIntelGenx Announces Initial Closing of atai Investment